Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent-Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS TrialGuillermo Garcia‐Manero, Uwe Platzbecker, Valeria Santini et al.|Blood|2024Cited by 4
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS TrialGuillermo Garcia‐Manero, Uwe Platzbecker, Sameer Kalsekar et al.|Advances in Therapy|2025Cited by 4
Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trialValeria Santini, Amer M. Zeidan, Matteo Della Porta et al.|Blood|2025Cited by 1
POSTER: MDS-730 Overall Survival (OS) and Duration of Red Blood Cell-Transfusion Independence (RBC-TI) for First-Line Erythropoiesis-Stimulating Agent (ESA)-Naïve Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated With Luspatercept (LUSPA) vs Epoetin Alfa (EA) in the COMMANDS TrialGuillermo Garcia‐Manero, Valeria Santini, Matteo Della Porta et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0